228 related articles for article (PubMed ID: 29389670)
1. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
[TBL] [Abstract][Full Text] [Related]
2. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
Tang X; Angst G; Haas M; Yang F; Wang C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
[TBL] [Abstract][Full Text] [Related]
3. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
4. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
[TBL] [Abstract][Full Text] [Related]
5. TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.
Magini A; Polchi A; Di Meo D; Mariucci G; Sagini K; De Marco F; Cassano T; Giovagnoli S; Dolcetta D; Emiliani C
Hum Mol Genet; 2017 Sep; 26(17):3303-3312. PubMed ID: 28637240
[TBL] [Abstract][Full Text] [Related]
6. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
8. Subependymal giant cell astrocytoma: a lesion with activated mTOR pathway and constant expression of glutamine synthetase.
Buccoliero AM; Caporalini C; Giordano F; Mussa F; Scagnet M; Moscardi S; Baroni G; Genitori L; Taddei GL
Clin Neuropathol; 2016; 35(5):295-301. PubMed ID: 27390104
[TBL] [Abstract][Full Text] [Related]
9. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle.
Zhou J; Shrikhande G; Xu J; McKay RM; Burns DK; Johnson JE; Parada LF
Genes Dev; 2011 Aug; 25(15):1595-600. PubMed ID: 21828270
[TBL] [Abstract][Full Text] [Related]
10. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
[TBL] [Abstract][Full Text] [Related]
11. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
13. Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
Ess KC; Kamp CA; Tu BP; Gutmann DH
Neurology; 2005 Apr; 64(8):1446-9. PubMed ID: 15851742
[TBL] [Abstract][Full Text] [Related]
14. Brain lesions in tuberous sclerosis complex. Review.
Grajkowska W; Kotulska K; Jurkiewicz E; Matyja E
Folia Neuropathol; 2010; 48(3):139-49. PubMed ID: 20924998
[TBL] [Abstract][Full Text] [Related]
15. Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma.
Siedlecka M; Szlufik S; Grajkowska W; Roszkowski M; Jóźwiak J
Folia Neuropathol; 2015; 53(1):8-14. PubMed ID: 25909870
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
17. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
18. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
19. [Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mTOR inhibitors].
Zitterbart K
Klin Onkol; 2014; 27(6):401-5. PubMed ID: 25493579
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of the MMP/TIMP Proteolytic System in Subependymal Giant Cell Astrocytomas in Patients With Tuberous Sclerosis Complex: Modulation of MMP by MicroRNA-320d In Vitro.
Bongaarts A; de Jong JM; Broekaart DWM; van Scheppingen J; Anink JJ; Mijnsbergen C; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Hainfellner JA; Feucht M; Borkowska J; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Scicluna BP; Schouten-van Meeteren AYN; van Vliet EA; Mühlebner A; Mills JD; Aronica E
J Neuropathol Exp Neurol; 2020 Jul; 79(7):777-790. PubMed ID: 32472129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
